Enanta Pharmaceuticals, Inc.
ENTA · NASDAQ
9/30/2025 | 9/30/2024 | 9/30/2023 | 9/30/2022 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $32 | $37 | $85 | $44 |
| Short-Term Investments | $157 | $211 | $285 | $205 |
| Receivables | $7 | $39 | $40 | $49 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $9 | $13 | $13 | $13 |
| Total Curr. Assets | $204 | $300 | $423 | $312 |
| Property Plant & Equip (Net) | $73 | $73 | $35 | $30 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $3 | $3 | $4 | $33 |
| Tax Assets | $0 | $0 | $0 | $5 |
| Other NC Assets | $0 | $0 | $1 | $1 |
| Total NC Assets | $76 | $77 | $39 | $69 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $281 | $377 | $462 | $381 |
| Liabilities | – | – | – | – |
| Payables | $2 | $8 | $4 | $6 |
| Short-Term Debt | $34 | $36 | $40 | $3 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $0 | $0 |
| Other Curr. Liab. | $13 | $14 | $18 | $21 |
| Total Curr. Liab. | $49 | $58 | $63 | $30 |
| LT Debt | $167 | $190 | $182 | $24 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $5 |
| Other NC Liab. | $0 | $0 | $1 | $0 |
| Total NC Liab. | $167 | $190 | $183 | $29 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $55 | $55 | $27 | $22 |
| Total Liabilities | $216 | $248 | $246 | $59 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$405 | -$323 | -$207 | -$73 |
| AOCI | -$0 | $0 | -$1 | -$4 |
| Other Equity | $470 | $451 | $425 | $398 |
| Total Equity | $65 | $129 | $217 | $321 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $281 | $377 | $462 | $381 |
| Net Debt | $169 | $189 | $137 | -$17 |